A Phase 2 trial in acute myeloid leukemia reported encouraging results for a combination of quizartinib and omacetaxine mepesuccinate. The study, published in Nature Communications in 2026, focused on a high-risk AML context where improved response durability remains an unmet need. The combination targets an aggressive biology using both an FLT3-directed agent (quizartinib) and an additional mechanism via omacetaxine, aiming to enhance efficacy beyond single-agent strategies. Next steps for the field will center on further cohort expansion and identifying which molecular or clinical subgroups benefit most from the regimen.